Cystic fibrosis

Shteinberg, Michal; Haq, Iram J; Polineni, Deepika; Davies, Jane C

doi:10.1016/s0140-6736(20)32542-3

Cited by 685Cystic Fibrosis Research AdvancesGenetic and Kidney Cyst DiseasesNeonatal Respiratory Health Research

Cystic fibrosis

Open access

Shteinberg, Michal, Haq, Iram J, Polineni, Deepika, Davies, Jane C·2021·The Lancet

DOI 10.1016/s0140-6736(20)32542-3

Open this paper in CoChat — free account

Abstract

Cystic fibrosis is a monogenic disease considered to affect at least 100 000 people worldwide. Mutations in CFTR, the gene encoding the epithelial ion channel that normally transports chloride and bicarbonate, lead to impaired mucus hydration and clearance. Classical cystic fibrosis is thus characterised by chronic pulmonary infection and inflammation, pancreatic exocrine insufficiency, male infertility, and might include several comorbidities such as cystic fibrosis-related diabetes or cystic fibrosis liver disease. This autosomal recessive disease is diagnosed in many regions following newborn screening, whereas in other regions, diagnosis is based on a group of recognised multiorgan clinical manifestations, raised sweat chloride concentrations, or CFTR mutations. Disease that is less easily diagnosed, and in some cases affecting only one organ, can be seen in the context of gene variants leading to residual protein function. Management strategies, including augmenting mucociliary clearance and aggressively treating infections, have gradually improved life expectancy for people with cystic fibrosis. However, restoration of CFTR function via new small molecule modulator drugs is transforming the disease for many patients. Clinical trial pipelines are actively exploring many other approaches, which will be increasingly needed as survival improves and as the population of adults with cystic fibrosis increases. Here, we present the current understanding of CFTR mutations, protein function, and disease pathophysiology, consider strengths and limitations of current management strategies, and look to the future of multidisciplinary care for those with cystic fibrosis.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(20)32542-3

Cites

194 of 194 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Standardisation of spirometry
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627 · see citing works
Identification of the Cystic Fibrosis Gene: Genetic Analysis
Kerem, B.-S., Rommens, J. M., Buchanan, J. A., Markiewicz, D., Cox, T. K., Chakravarti, A., Buchwald, M., & Tsui, L.-C. (1989) · Science · doi:10.1126/science.2570460 · Cited by 4,142 · see citing works
Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies
Pang, Z., Raudonis, R., Glick, B. R., Lin, T., & Cheng, Z. (2018) · Biotechnology Advances · doi:10.1016/j.biotechadv.2018.11.013 · Cited by 2,375 · see citing works
Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele
Middleton, P. G., Mall, M. A., Dřevínek, P., Lands, L. C., McKone, E. F., Polineni, D., Ramsey, B. W., Taylor-Cousar, J. L., Tullis, E., Vermeulen, F., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908639 · Cited by 2,198 · see citing works
Self-citation
A CFTR Potentiator in Patients with Cystic Fibrosis and the <i>G551D</i> Mutation
Ramsey, B. W., Davies, J., McElvaney, N. G., Tullis, E., Bell, S. C., Dřevínek, P., Griese, M., McKone, E. F., Wainwright, C. E., Konstan, M. W., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105185 · Cited by 2,195 · see citing works
Self-citation
Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del <i>CFTR</i>
Wainwright, C. E., Elborn, J. S., Ramsey, B. W., Marigowda, G., Huang, X., Cipolli, M., Colombo, C., Davies, J. C., De Boeck, K., Flume, P. A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1409547 · Cited by 1,622 · see citing works
Self-citation
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial
Heijerman, H. G. M., McKone, E. F., Downey, D. G., Van Braeckel, E., Rowe, S. M., Tullis, E., Mall, M. A., Welter, J. J., Ramsey, B. W., McKee, C. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32597-8 · Cited by 1,414 · see citing works
Intermittent Administration of Inhaled Tobramycin in Patients with Cystic Fibrosis
Ramsey, B. W., PEPE, M. S., Quan, J. M., Otto, K., Montgomery, A. B., Williams‐Warren, J., Vasiljev-K, M., Borowitz, D., Bowman, C. M., Marshall, B. C., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901073400104 · Cited by 1,296 · see citing works
The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult lung and heart–lung transplantation Report—2019; Focus theme: donor and recipient size match
Chambers, D. C., Cherikh, W. S., Harhay, M. O., Hayes, D., Hsich, E., Khush, K. K., Meiser, B., Potena, L., Rossano, J. W., Toll, A. E., et al. (2019) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2019.08.001 · Cited by 1,269 · see citing works
The future of cystic fibrosis care: a global perspective
Bell, S. C., Mall, M. A., Gutierrez, H., Macek, M., Madge, S. L., Davies, J. C., Burgel, P., Tullis, E., Castaños, C., Castellani, C., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30337-6 · Cited by 1,042 · see citing works
Self-citation
A functional CFTR assay using primary cystic fibrosis intestinal organoids
Dekkers, J. F., Wiegerinck, C. L., de Jonge, H. R., Bronsveld, I., Janssens, H. M., de Winter-de Groot, K. M., Brandsma, A. M., de Jong, N. W. M., Bijvelds, M. J. C., Scholte, B. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3201 · Cited by 999 · see citing works
Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation
Farrell, P. M., White, T. B., Ren, C. L., Hempstead, S. E., Accurso, F., Derichs, N., Howenstine, M., McColley, S. A., Rock, M., Rosenfeld, M., et al. (2017) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2016.09.064 · Cited by 953 · see citing works
A Periciliary Brush Promotes the Lung Health by Separating the Mucus Layer from Airway Epithelia
Button, B. M., Cai, L.-H., Ehré, C., Kesımer, M., Hill, D. B., Sheehan, J. K., Boucher, R. C., & Rubinstein, M. (2012) · Science · doi:10.1126/science.1223012 · Cited by 864 · see citing works
Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung
Pezzulo, A. A., Tang, X. X., Hoegger, M. J., Alaiwa, M. H. A., Ramachandran, S. S., Moninger, T. O., Karp, P. H., Wohlford-Lenane, C., Haagsman, H. P., van Eijk, M., et al. (2012) · Nature · doi:10.1038/nature11130 · Cited by 807 · see citing works
Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del
Taylor-Cousar, J. L., Munck, A., McKone, E. F., van der Ent, C. K., Moeller, A., Simard, C., Wang, L. T., Ingenito, E. P., McKee, C., Lu, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709846 · Cited by 794 · see citing works
British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD)
HAWORTH, C. S., Banks, J., Capstick, T., Fisher, A. J., Gorsuch, T., Laurenson, I. F., Leitch, A., Loebinger, M. R., Milburn, H. J., Nightingale, M., et al. (2017) · Thorax · doi:10.1136/thoraxjnl-2017-210927 · Cited by 791 · see citing works
Involvement of Nitric Oxide in Biofilm Dispersal of Pseudomonas aeruginosa
Barraud, N., Hassett, D. J., Hwang, S.-H., Rice, S. A., Kjelleberg, S. J., & Webb, J. S. (2006) · Journal of Bacteriology · doi:10.1128/jb.00779-06 · Cited by 786 · see citing works
ECFS best practice guidelines: the 2018 revision
Castellani, C., Duff, A. J. A., Bell, S. C., Heijerman, H. G. M., Munck, A., Ratjen, F., Sermet-Gaudelus, I., Southern, K. W., Barben, J., Flume, P. A., et al. (2018) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2018.02.006 · Cited by 765 · see citing works
New concepts of the pathogenesis of cystic fibrosis lung disease
Boucher, R. C. (2003) · European Respiratory Journal · doi:10.1183/09031936.03.00057003 · Cited by 642 · see citing works
CYSTIC FIBROSIS: GENOTYPIC AND PHENOTYPIC VARIATIONS
Zielenski, J., & Tsui, L. (1995) · Annual Review of Genetics · doi:10.1146/annurev.ge.29.120195.004021 · Cited by 636 · see citing works
Risk Factors for Bronchiectasis in Children with Cystic Fibrosis
Sly, P. D., Gangell, C. L., Chen, L., Ware, R. S., Ranganathan, S., Mott, L. S., Murray, C. P. J., & Stick, S. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301725 · Cited by 596 · see citing works
From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations
Veit, G., Avramescu, R. G., Chiang, A., Houck, S. A., Cai, Z., Peters, K. W., Hong, J. S., Pollard, H. B., Guggino, W. B., Balch, W. E., et al. (2016) · Molecular Biology of the Cell · doi:10.1091/mbc.e14-04-0935 · Cited by 582 · see citing works
Lung Disease at Diagnosis in Infants with Cystic Fibrosis Detected by Newborn Screening
Sly, P. D., Brennan, S., Gangell, C. L., de Klerk, N. H., Murray, C. P. J., Mott, L. S., Stick, S. M., Robinson, P. J., ROBERTSON, C. F., & Ranganathan, S. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200901-0069oc · Cited by 552 · see citing works
ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis
Turck, D., Braegger, C., Colombo, C., Declercq, D., Morton, A. M., Pancheva, R., Robberecht, E., Stern, M., Strandvik, B., Wolfe, S., et al. (2016) · Clinical Nutrition · doi:10.1016/j.clnu.2016.03.004 · Cited by 527 · see citing works
Prevalence of depression and anxiety in patients with cystic fibrosis and parent caregivers: results of The International Depression Epidemiological Study across nine countries
Quittner, A. L., Goldbeck, L., Abbott, J., Duff, A., Lambrecht, P., Solé, A., Tibosch, M. M., Bergsten Brucefors, A., Yüksel, H., Catastini, P., et al. (2014) · Thorax · doi:10.1136/thoraxjnl-2014-205983 · Cited by 524 · see citing works
Tezacaftor–Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis
Rowe, S. M., Daines, C., Ringshausen, F. C., Kerem, E., Wilson, J., Tullis, E., Nair, N., Simard, C., Han, L., Ingenito, E. P., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709847 · Cited by 522 · see citing works
Self-citation
Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial
Wolter, J. M. (2002) · Thorax · doi:10.1136/thorax.57.3.212 · Cited by 516 · see citing works
Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation
Clancy, J. P., Rowe, S. M., Accurso, F. J., Aitken, M. L., Amin, R. S., Ashlock, M. A., Ballmann, M., Boyle, M., Bronsveld, I., Campbell, P. W., et al. (2011) · Thorax · doi:10.1136/thoraxjnl-2011-200393 · Cited by 514 · see citing works
Clinical Mechanism of the Cystic Fibrosis Transmembrane Conductance Regulator Potentiator Ivacaftor in G551D-mediated Cystic Fibrosis
Rowe, S. M., Heltshe, S. L., Gonska, T., Donaldson, S. H., Borowitz, D., Gelfond, D., Sagel, S. D., Khan, U., Mayer-Hamblett, N., Van Dalfsen, J. M., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201404-0703oc · Cited by 492 · see citing works
International Committee on Mental Health in Cystic Fibrosis: Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus statements for screening and treating depression and anxiety.
Quittner, A. L., Abbott, J., Georgiopoulos, A. M., Goldbeck, L., Smith, B., Hempstead, S. E., Marshall, B., Sabadosa, K. A., & Elborn, S. (2016) · Thorax · doi:10.1136/thoraxjnl-2015-207488 · Cited by 450 · see citing works
Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial
Alton, E. W. F. W., Armstrong, D. K., Ashby, D., Bayfield, K. J., Bilton, D., Bloomfield, E. V., Boyd, A. C., Brand, J., Buchan, R., Calcedo, R., et al. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00245-3 · Cited by 428 · see citing works
Self-citation
Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease
Debray, D., Kelly, D. A., Houwen, R. H. J., Strandvik, B., & Colombo, C. (2011) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(11)60006-4 · Cited by 428 · see citing works
Recommendations for the classification of diseases as CFTR-related disorders
Bombieri, C., Claustres, M., Boeck, K. D., Derichs, N., DODGE, J. A., Girodon, E., Sermet‐Gaudelus, I., Schwarz, M. J., Tzetis, M., Wilschanski, M. A., et al. (2011) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(11)60014-3 · Cited by 425 · see citing works
Infection Prevention and Control Guideline for Cystic Fibrosis: 2013 Update
Saiman, L. M., Siegel, J. D., LiPuma, J. J., Brown, R. F., Bryson, E. A., Chambers, M. J., Downer, V. S., Fliege, J. D., Hazle, L., Jain, M., et al. (2014) · Infection Control and Hospital Epidemiology · doi:10.1086/676882 · Cited by 389 · see citing works
Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function Reduces Airway Bacteria and Inflammation in People with Cystic Fibrosis and Chronic Lung Infections
Hisert, K. B., Heltshe, S. L., Pope, C. E., Jorth, P. A., Wu, X., Edwards, R. M., Radey, M. C., Accurso, F. J., Wolter, D. J., Cooke, G., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201609-1954oc · Cited by 387 · see citing works
Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study
Griffith, D. E., Eagle, G. L., Thomson, R. M., Aksamit, T. R., Hasegawa, N., Morimoto, K., Addrizzo-Harris, D. J., O’Donnell, A. E., Marras, T. K., Flume, P. A., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201807-1318oc · Cited by 362 · see citing works
Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2–5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study
Davies, J. C., Cunningham, S., Harris, W. T., Lapey, A., Regelmann, W. E., Sawicki, G. S., Southern, K. W., Robertson, S. M. C., Green, Y., Cooke, J., et al. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00545-7 · Cited by 347 · see citing works
Self-citation
Bicarbonate and functional CFTR channel are required for proper mucin secretion and link cystic fibrosis with its mucus phenotype
Gustafsson, J. K., Ermund, A., Ambort, D., Johansson, M., Nilsson, H. E., Thorell, K., Hebert, H., Sjövall, H., & Hansson, G. C. (2012) · The Journal of Experimental Medicine · doi:10.1084/jem.20120562 · Cited by 345 · see citing works
Cystic Fibrosis Pulmonary Guidelines: Airway Clearance Therapies
Flume, P. A., Robinson, K. A., O'Sullivan, B. P., Finder, J. D., Vender, R. L., Willey-Courand, D.-B., White, T. B., & Marshall, B. C. (2009) · Respiratory Care · doi:10.4187/respcare.09540522 · Cited by 340 · see citing works
Effective mucus clearance is essential for respiratory health
Randell, S. H., & Boucher, R. C. (2006) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2006-0082sf · Cited by 335 · see citing works
Bronchiectasis in Infants and Preschool Children Diagnosed with Cystic Fibrosis after Newborn Screening
Stick, S. M., Brennan, S., Murray, C. P. J., Douglas, T. A., von Ungern-Sternberg, B. S., Garratt, L. W., Gangell, C. L., de Klerk, N. H., Linnane, B. M., Ranganathan, S., et al. (2009) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2009.05.005 · Cited by 333 · see citing works
Effect of Azithromycin on Pulmonary Function in Patients With Cystic Fibrosis Uninfected With Pseudomonas aeruginosa A Randomized Controlled Trial
Saiman, L. M. (2010) · JAMA · doi:10.1001/jama.2010.563 · Cited by 326 · see citing works
Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Hewer, S. C. L., & Smyth, A. R. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004197.pub4 · Cited by 324 · see citing works
Efficacy and safety of lumacaftor and ivacaftor in patients aged 6–11 years with cystic fibrosis homozygous for F508del-CFTR : a randomised, placebo-controlled phase 3 trial
Ratjen, F. A., Hug, C., Marigowda, G., Tian, S., Huang, X., Stanojevic, S., Milla, C. E., Robinson, P. D., Waltz, D. A., Davies, J. C., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30215-1 · Cited by 297 · see citing works
Self-citation
Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study
Konstan, M. W., McKone, E. F., Moss, R. B., Marigowda, G., Tian, S., Waltz, D. A., Huang, X., Lubarsky, B., Rubin, J. L., Millar, S. J., et al. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30427-1 · Cited by 287 · see citing works
Future trends in cystic fibrosis demography in 34 European countries
Burgel, P., Bellis, G., Olesen, H. V., Viviani, L., Zolin, A., Blasi, F., & Elborn, J. S. (2015) · European Respiratory Journal · doi:10.1183/09031936.00196314 · Cited by 280 · see citing works
Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries
Volkova, N., Moy, K., Evans, J., Campbell, D., Tian, S., Simard, C., Higgins, M., Konstan, M. W., Sawicki, G. S., Elbert, A., et al. (2020) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.05.015 · Cited by 258 · see citing works
The Global Lung Function Initiative (GLI) Network: bringing the world’s respiratory reference values together
Cooper, B. G., Stocks, J., Hall, G. L., Culver, B. H., Steenbruggen, I., Carter, K. W., Thompson, B. R., Graham, B. L., Miller, M. R., Ruppel, G. L., et al. (2017) · Breathe · doi:10.1183/20734735.012717 · Cited by 256 · see citing works
Type of CFTR Mutation Determines Risk of Pancreatitis in Patients With Cystic Fibrosis
Ooi, C. Y., Dorfman, R., Cipolli, M., Gonska, T. Y., Castellani, C., Keenan, K., Freedman, S. D., Zielenski, J., Berthiaume, Y., Corey, M. L., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.09.046 · Cited by 255 · see citing works
Epidemiology, Biology, and Impact of Clonal Pseudomonas aeruginosa Infections in Cystic Fibrosis
Parkins, M. D., Somayaji, R., & Waters, V. J. (2018) · Clinical Microbiology Reviews · doi:10.1128/cmr.00019-18 · Cited by 252 · see citing works
Lung transplant referral for individuals with cystic fibrosis: cystic Fibrosis Foundation consensus guidelines
Ramos, K. J., Smith, P. J., McKone, E. F., Pilewski, J. M., Lucy, A., Hempstead, S. E., Tallarico, E., Faro, A., Rosenbluth, D. B., Gray, A. L., et al. (2019) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.03.002 · Cited by 227 · see citing works
Phage therapy is highly effective against chronic lung infections withPseudomonas aeruginosa
Waters, E. M., Neill, D. R., Kaman, B., Sahota, J. S., Clokie, M. R. J., Winstanley, C., & Kadioglu, A. (2017) · Thorax · doi:10.1136/thoraxjnl-2016-209265 · Cited by 216 · see citing works
Vitamin D supplementation for cystic fibrosis
Ferguson, J. H., & Chang, A. B. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007298.pub4 · Cited by 215 · see citing works
Comparison of Lung Clearance Index and Magnetic Resonance Imaging for Assessment of Lung Disease in Children with Cystic Fibrosis
Stahl, M., Wielpütz, M. O., Graeber, S. Y., Joachim, C., Sommerburg, O., Kauczor, H., Puderbach, M., Eichinger, M., & Mall, M. A. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201604-0893oc · Cited by 213 · see citing works
Guidelines for the diagnosis and management of distal intestinal obstruction syndrome in cystic fibrosis patients
Colombo, C., Ellemunter, H., Houwen, R. H. J., Munck, À., Taylor, C., & Wilschanski, M. A. (2011) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(11)60005-2 · Cited by 198 · see citing works
Mucus accumulation in the lungs precedes structural changes and infection in children with cystic fibrosis
Esther, C. R., Muhlebach, M. S., Ehré, C., Hill, D. B., Wolfgang, M. C., Kesımer, M., Ramsey, K. A., Markovetz, M. R., Garbarine, I. C., Forest, M. G., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav3488 · Cited by 198 · see citing works
Cystic fibrosis carriers are at increased risk for a wide range of cystic fibrosis-related conditions
Miller, A. C., Comellas, A. P., Hornick, D. B., Stoltz, D. A., Cavanaugh, J. E., Gerke, A. K., Welsh, M. J., Zabner, J., & Polgreen, P. M. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1914912117 · Cited by 198 · see citing works
Cystic fibrosis colorectal cancer screening consensus recommendations
Hadjiliadis, D., Khoruts, A., Zauber, A. G., Hempstead, S. E., Maisonneuve, P., Lowenfels, A. B., Braid, A. L., Cullina, J., Daggett, A., Fink, A., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2017.12.012 · Cited by 195 · see citing works
Development of Novel Aminoglycoside (NB54) with Reduced Toxicity and Enhanced Suppression of Disease-Causing Premature Stop Mutations
Nudelman, I., Rebibo-Sabbah, A., Cherniavsky, M., Белахов, В. В., Hainrichson, M., Chen, F., Schacht, J., Pilch, D. S., Ben‐Yosef, T., & Baasov, T. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801640k · Cited by 190 · see citing works
In utero and postnatal VX-770 administration rescues multiorgan disease in a ferret model of cystic fibrosis
Sun, X., Yi, Y., Yan, Z., Rosen, B. H., Liang, B., Winter, M. C., Evans, T. I. A., Rotti, P. G., Yu, Y., Gray, J. S., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau7531 · Cited by 190 · see citing works
Cystic fibrosis–related diabetes is caused by islet loss and inflammation
Hart, N. J., Aramandla, R., Poffenberger, G., Fayolle, C., Thames, A. H., Bautista, A., Spigelman, A. F., Babon, J. A. B., DeNicola, M., Dadi, P. K., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.98240 · Cited by 183 · see citing works
Molecular Basis of Azithromycin-Resistant Pseudomonas aeruginosa Biofilms
Gillis, R. J., White, K. G., Choi, K., Wagner, V., Schweizer, H. P., & Iglewski, B. H. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3858-3867.2005 · Cited by 183 · see citing works
Risk of gastrointestinal cancers in patients with cystic fibrosis: a systematic review and meta-analysis
Yamada, A., Komaki, Y., Komaki, F., Micić, D., Zullow, S., & Sakuraba, A. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30188-8 · Cited by 182 · see citing works
Cystic Fibrosis Screen Positive, Inconclusive Diagnosis (CFSPID): A new designation and management recommendations for infants with an inconclusive diagnosis following newborn screening
Munck, À., Mayell, S. J., Winters, V., Shawcross, A., Derichs, N., Parad, R. B., Barben, J., & Southern, K. W. (2015) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2015.01.001 · Cited by 173 · see citing works
ISPAD Clinical Practice Consensus Guidelines 2018: management of cystic fibrosis-related diabetes in children and adolescents
Moran, A., Pillay, K., Becker, D., Granados, A., Hameed, S., & Acerini, C. L. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12732 · Cited by 171 · see citing works
Overcoming Drug Resistance with Alginate Oligosaccharides Able To Potentiate the Action of Selected Antibiotics
Khan, S. S., Tøndervik, A., Sletta, H., Klinkenberg, G., Emanuel, C., Onsøyen, E., Myrvold, R., Howe, R. A., Walsh, T. R., Hill, K. E., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00525-12 · Cited by 171 · see citing works
Pseudomonas aeruginosa infection in cystic fibrosis: pathophysiological mechanisms and therapeutic approaches
Lund‐Palau, H., Turnbull, A. R., Bush, A., Bardin, E., Cameron, L. P., Soren, O., Wierre-Gore, N., Alton, E. W. F. W., Bundy, J. G., Connett, G. J., et al. (2016) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2016.1177460 · Cited by 165 · see citing works
Self-citation
Meconium ileus in Cystic Fibrosis
Sathe, M., & Houwen, R. H. J. (2017) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2017.06.007 · Cited by 165 · see citing works
The Cystic Fibrosis of Exocrine PancreasPreprint
Wilschanski, M. A., & Novak, I. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009746 · Cited by 160 · see citing works
Cystic Fibrosis Foundation consensus guidelines for the care of individuals with advanced cystic fibrosis lung disease
Kapnadak, S. G., DiMango, E., Hadjiliadis, D., Hempstead, S. E., Tallarico, E., Pilewski, J. M., Faro, A., Albright, J. T., Benden, C., Blair, S., et al. (2020) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2020.02.015 · Cited by 159 · see citing works
Ursodeoxycholic acid for cystic fibrosis-related liver disease
Cheng, K., Ashby, D., & Smyth, R. L. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000222.pub4 · Cited by 157 · see citing works
Synthetic Aminoglycosides Efficiently Suppress Cystic Fibrosis Transmembrane Conductance Regulator Nonsense Mutations and Are Enhanced by Ivacaftor
Xue, X., Mutyam, V., Tang, L., Biswas, S., Du, M., Jackson, L. A., Dai, Y., Белахов, В. В., Shalev, M., Chen, F., et al. (2013) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2013-0282oc · Cited by 152 · see citing works
Intestinal current measurement for diagnostic classification of patients with questionable cystic fibrosis: validation and reference data
Derichs, N., Sanz, J., von Känel, T., Stolpe, C., Zapf, A., Tümmler, B., Gallati, S., & Ballmann, M. (2010) · Thorax · doi:10.1136/thx.2009.125088 · Cited by 145 · see citing works
A Functional Anatomic Defect of the Cystic Fibrosis Airway
Birket, S. E., Chu, K. K., Liu, L., Houser, G. H., Diephuis, B. J., Wilsterman, E. J., Dierksen, G. A., Mazur, M., Shastry, S., Li, Y., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201404-0670oc · Cited by 143 · see citing works
Co-encapsulation of gallium with gentamicin in liposomes enhances antimicrobial activity of gentamicin against Pseudomonas aeruginosa
Halwani, M., Yebio, B., Suntres, Z. E., Alipour, M., Azghani, A. O., & Omri, A. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn422 · Cited by 140 · see citing works
Features of Severe Liver Disease With Portal Hypertension in Patients With Cystic Fibrosis
Stonebraker, J. R., Ooi, C. Y., Pace, R. G., Corvol, H., Knowles, M. R., Durie, P. R., & Ling, S. C. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.03.041 · Cited by 138 · see citing works
ERS/TSANZ Task Force Statement on the management of reproduction and pregnancy in women with airways diseases
Middleton, P. G., Gade, E. J., Aguilera, C., Mackillop, L. H., Button, B., Coleman, C., Johnson, B. A., Albrechtsen, C. K., Edenborough, F. P., Comas, D. R., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.01208-2019 · Cited by 138 · see citing works
A multinational report to characterise SARS-CoV-2 infection in people with cystic fibrosis
Cosgriff, R., Ahern, S., Bell, S. C., Brownlee, K. G., Burgel, P., Byrnes, C., Corvol, H., Cheng, S. Y., Elbert, A., Faro, A., et al. (2020) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2020.04.012 · Cited by 138 · see citing works
Cystic Fibrosis Transmembrane Conductance Regulator-Related Metabolic Syndrome and Cystic Fibrosis Screen Positive, Inconclusive Diagnosis
Ren, C. L., Borowitz, D., Gonska, T. Y., Howenstine, M. S., Levy, H., Massie, J., Milla, C. E., Munck, À., & Southern, K. W. (2017) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2016.09.066 · Cited by 132 · see citing works
Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Hewer, S. C. L., & Smyth, A. R. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004197.pub5 · Cited by 127 · see citing works
Infection Is Not Required for Mucoinflammatory Lung Disease in CFTR-Knockout Ferrets
Rosen, B. H., Evans, T. I. A., Moll, S. R., Gray, J. S., Liang, B., Sun, X., Zhang, Y., Jensen-Cody, C. W., Swatek, A. M., Zhou, W., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201708-1616oc · Cited by 124 · see citing works
Antimicrobial susceptibility testing (AST) and associated clinical outcomes in individuals with cystic fibrosis: A systematic review
Somayaji, R., Parkins, M. D., Shah, A., Martiniano, S. L., Tunney, M. M., Kahle, J. S., Waters, V. J., Elborn, J. S., Bell, S. C., Flume, P. A., et al. (2019) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.01.008 · Cited by 121 · see citing works
Emerging Therapeutic Approaches for Cystic Fibrosis. From Gene Editing to Personalized Medicine
Pranke, I. M., Golec, A., Hinzpeter, A., Edelman, A., & Sermet‐Gaudelus, I. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00121 · Cited by 121 · see citing works
Report of the European Respiratory Society/European Cystic Fibrosis Society task force on the care of adults with cystic fibrosis
Elborn, J. S., Bell, S. C., Madge, S. L., Burgel, P., Castellani, C., Conway, S., Rijcke, K. D., Dembski, B., Dřevı́nek, P., Heijerman, H. G. M., et al. (2015) · European Respiratory Journal · doi:10.1183/13993003.00592-2015 · Cited by 120 · see citing works
Diagnosis of Cystic Fibrosis in Screened Populations
Farrell, P. M., White, T. B., Howenstine, M. S., Munck, À., Parad, R. B., Rosenfeld, M., Sommerburg, O., Accurso, F. J., Davies, J. C., Rock, M. J., et al. (2017) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2016.09.065 · Cited by 120 · see citing works
Self-citation
Effect of Azithromycin on Systemic Markers of Inflammation in Patients With Cystic Fibrosis Uninfected With Pseudomonas aeruginosa
Ratjen, F. A., Saiman, L. M., Mayer-Hamblett, N., Lands, L. C., Kloster, M., Thompson, V., Emmett, P., Marshall, B. C., Accurso, F. J., Sagel, S. D., et al. (2012) · CHEST Journal · doi:10.1378/chest.12-0628 · Cited by 120 · see citing works
Preventive Inhalation of Hypertonic Saline in Infants with Cystic Fibrosis (PRESIS). A Randomized, Double-Blind, Controlled Study
Stahl, M., Wielpütz, M. O., Ricklefs, I., Dopfer, C., Barth, S., Schlegtendal, A., Graeber, S. Y., Sommerburg, O., Diekmann, G., Hüsing, J., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201807-1203oc · Cited by 116 · see citing works
The Spectrum of CFTR Variants in Nonwhite Cystic Fibrosis Patients
Schrijver, I., Pique, L. M., Graham, S., Pearl, M., Cherry, A. M., & Kharrazi, M. (2015) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2015.07.005 · Cited by 112 · see citing works
Good effect of IgY against Pseudomonas aeruginosa infections in cystic fibrosis patients
Nilsson, E., Larsson, A., Olesen, H. V., Wejåker, P., & Kollberg, H. (2008) · Pediatric Pulmonology · doi:10.1002/ppul.20875 · Cited by 111 · see citing works
Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis
Elphick, H., & Southern, K. W. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002204.pub4 · Cited by 110 · see citing works
Pulmonary exacerbations in cystic fibrosis
Stenbit, A. E., & Flume, P. A. (2011) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e32834b8c04 · Cited by 105 · see citing works
Dornase alfa for cystic fibrosis
Yang, C., & Montgomery, M. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001127.pub4 · Cited by 101 · see citing works
Antipseudomonal Bacteriophage Reduces Infective Burden and Inflammatory Response in Murine Lung
Pabary, R., Singh, C., Morales, S., Bush, A., Alshafi, K., Bilton, D., Alton, E. W. F. W., Smithyman, A. M., & Davies, J. C. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01426-15 · Cited by 101 · see citing works
Self-citation
Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial
Mayer-Hamblett, N., Retsch‐Bogart, G. Z., Kloster, M., Accurso, F. J., Rosenfeld, M., Albers, G. M., Black, P., Brown, P. S., Cairns, A., Davis, S. D., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201802-0215oc · Cited by 99 · see citing works
Airway surface liquid pH is not acidic in children with cystic fibrosis
Schultz, A., Puvvadi, R., Borisov, S. M., Shaw, N. C., Klimant, I., Berry, L. J., Montgomery, S., Nguyen, T., Kreda, S. M., Kicic, A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00532-5 · Cited by 98 · see citing works
Cystic fibrosis related diabetes in Europe: prevalence, risk factors and outcome; Olesen et al
Olesen, H. V., Drevinek, P., Gulmans, V. A., Hatziagorou, E., Jung, A., Mei-Zahav, M., Stojnic, N., Thomas, M., & Zolin, A. (2020) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.10.009 · Cited by 95 · see citing works
Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa
Wainwright, C. E., Quittner, A. L., Geller, D. E., Nakamura, C., Wooldridge, J. L., Gibson, R. L., Lewis, S., & Montgomery, A. B. (2011) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2011.02.007 · Cited by 94 · see citing works
A novel treatment of cystic fibrosis acting on-target: cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTR
Tosco, A., De Gregorio, F., Esposito, S., De Stefano, D., Sana, I., Ferrari, E., Sepe, A., Salvadori, L., Buonpensiero, P., Di Pasqua, A., et al. (2016) · Cell Death & Differentiation · doi:10.1038/cdd.2016.22 · Cited by 92 · see citing works
Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis
Smith, S., Rowbotham, N. J., & Regan, K. H. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001021.pub3 · Cited by 92 · see citing works
Antibiotic management of lung infections in cystic fibrosis. II. Nontuberculous mycobacteria, anaerobic bacteria, and fungi.
Chmiel, J., Aksamit, T., Chotirmall, S. H., Dasenbrook, E., Elborn, J., Lipuma, J., Ranganathan, S., Waters, V., & Ratjen, F. (2014) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201405-203as · Cited by 89 · see citing works
Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations
Sanders, D. B., Solomon, G. M., Beckett, V. V., West, N. E., Daines, C. L., Heltshe, S. L., VanDevanter, D. R., Spahr, J. E., Gibson, R. L., Nick, J. A., et al. (2017) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2017.04.005 · Cited by 87 · see citing works
Defining antimicrobial resistance in cystic fibrosis
Kidd, T. J., Cantón, R., Ekkelenkamp, M. B., Johansen, H. K., Gilligan, P. H., LiPuma, J. J., Bell, S. C., Elborn, J. S., Flume, P. A., VanDevanter, D. R., et al. (2018) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2018.08.014 · Cited by 86 · see citing works
Pulmonary Aspergillosis: An Evolving Challenge for Diagnosis and Treatment
Russo, A., Tiseo, G., Falcone, M., & Menichetti, F. (2020) · Infectious Diseases and Therapy · doi:10.1007/s40121-020-00315-4 · Cited by 86 · see citing works
A New Class of Safe Oligosaccharide Polymer Therapy To Modify the Mucus Barrier of Chronic Respiratory Disease
Pritchard, M., Powell, L. C., Menzies, G. E., Lewis, P. D., Hawkins, K. M., Wright, C. J., Doull, I. J. M., Walsh, T. R., Onsøyen, E., Dessen, A., et al. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00794 · Cited by 85 · see citing works
The Delta F508 Mutation in Cystic Fibrosis and Impact on Sinus Development
Woodworth, B. A., Ahn, C. N., Flume, P. A., & Schlosser, R. J. (2007) · American Journal of Rhinology · doi:10.2500/ajr.2007.21.2905 · Cited by 84 · see citing works
Positive expiratory pressure physiotherapy for airway clearance in people with cystic fibrosis
McIlwaine, M. P., Button, B., & Nevitt, S. J. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003147.pub5 · Cited by 82 · see citing works
Neonates with cystic fibrosis have a reduced nasal liquid pH; A small pilot study
Alaiwa, M. H. A., Beer, A. M., Pezzulo, A. A., Launspach, J. L., Horan, R. A., Stoltz, D. A., Starner, T. D., Welsh, M. J., & Zabner, J. (2014) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2013.12.006 · Cited by 82 · see citing works
Airway surface liquid acidification initiates host defense abnormalities in Cystic Fibrosis
Simonin, J., Bille, E., Crambert, G., Noël, S., Dréano, E., Edwards, A., Hatton, A., Pranke, I. M., Villeret, B., Cottart, C., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-42751-4 · Cited by 82 · see citing works
The emerging burden of liver disease in cystic fibrosis patients: A UK nationwide study
Toledano, M. B., Mukherjee, S. K., Howell, J. A., Westaby, D., Khan, S. A., Bilton, D., & Simmonds, N. J. (2019) · PLoS ONE · doi:10.1371/journal.pone.0212779 · Cited by 81 · see citing works
Cysteamine re-establishes the clearance of Pseudomonas aeruginosa by macrophages bearing the cystic fibrosis-relevant F508del-CFTR mutation
Ferrari, E., Monzani, R., Villella, V. R., Esposito, S., Saluzzo, F., Rossin, F., D’Eletto, M., Tosco, A., Gregorio, F. D., Izzo, V., et al. (2017) · Cell Death and Disease · doi:10.1038/cddis.2016.476 · Cited by 76 · see citing works
Diagnosis of Cystic Fibrosis in Nonscreened Populations
Sosnay, P. R., White, T. B., Farrell, P. M., Ren, C. L., Derichs, N., Howenstine, M. S., Nick, J. A., & Boeck, K. D. (2017) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2016.09.068 · Cited by 76 · see citing works
Suppression of CFTR premature termination codons and rescue of CFTR protein and function by the synthetic aminoglycoside NB54
Rowe, S. M., Sloane, P. A., Tang, L. P., Backer, K., Mazur, M., Buckley-Lanier, J. A., Nudelman, I., Белахов, В. В., Bebők, Z., Schwiebert, E. M., et al. (2011) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0787-6 · Cited by 74 · see citing works
A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients
Flume, P. A., VanDevanter, D. R., Morgan, E. E., Dudley, M. N., Loutit, J., Bell, S. C., Kerem, E., Fischer, R., Smyth, A. R., Aaron, S. D., et al. (2016) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2015.12.004 · Cited by 74 · see citing works
The Physiology and Pathophysiology of Pancreatic Ductal Secretion
Pallagi, P., Hegyi, P. J., & Rakonczay, Z. (2015) · Pancreas · doi:10.1097/mpa.0000000000000421 · Cited by 74 · see citing works
The role for neutrophil extracellular traps in cystic fibrosis autoimmunity
Skopelja‐Gardner, S., Hamilton, B. J., Jones, J. D. G., Yang, M., Mamula, M. J., Ashare, A., Gifford, A. H., & Rigby, W. F. C. (2016) · JCI Insight · doi:10.1172/jci.insight.88912 · Cited by 74 · see citing works
Failure to conceive in women with CF is associated with pancreatic insufficiency and advancing age
Shteinberg, M., Lulu, A. B., Downey, D. G., Blumenfeld, Z., Rousset‐Jablonski, C., Perceval, M., Colombo, A. I. M., Stein, N., Livnat, G., Gur, M., et al. (2018) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2018.10.009 · Cited by 74 · see citing works
Self-citation
ENaC inhibition in cystic fibrosis: potential role in the new era of CFTR modulator therapies
Mall, M. A. (2020) · European Respiratory Journal · doi:10.1183/13993003.00946-2020 · Cited by 74 · see citing works
Predictive factors for lumacaftor/ivacaftor clinical response
Masson, A., Schneider‐Futschik, E. K., Baatallah, N., Nguyen‐Khoa, T., Girodon, E., Hatton, A., Flament, T., Bourgeois, M. L., Chedevergne, F., Bailly-Botuha, C., et al. (2018) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2018.12.011 · Cited by 73 · see citing works
Cystic fibrosis bone disease treatment: Current knowledge and future directions
Putman, M. S., Anabtawi, A., Le, T. N. H., Tangpricha, V., & Sermet‐Gaudelus, I. (2019) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.08.017 · Cited by 72 · see citing works
A Nanoscale Characterization of the Interaction of a Novel Alginate Oligomer with the Cell Surface and Motility of Pseudomonas aeruginosa
Powell, L. C., Pritchard, M., Emanuel, C., Onsøyen, E., Rye, P. D., Wright, C. J., Hill, K. E., & Thomas, D. W. (2013) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2013-0287oc · Cited by 68 · see citing works
Pooled analysis of two large randomised phase III inhaled mannitol studies in cystic fibrosis
Bilton, D., Bellon, G., Charlton, B., Cooper, P., Boeck, K. D., Flume, P. A., Fox, H. G., Gallagher, C. G., Geller, D. E., Haarman, E. G., et al. (2012) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2012.11.002 · Cited by 68 · see citing works
Growth and Nutrition in Cystic Fibrosis
Brownell, J. N., Bashaw, H., & Stallings, V. A. (2019) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0039-1696726 · Cited by 68 · see citing works
Pharmaceuticals Targeting Nonsense Mutations in Genetic Diseases
Rowe, S. M., & Clancy, J. P. (2009) · BioDrugs · doi:10.2165/00063030-200923030-00003 · Cited by 67 · see citing works
SharedPseudomonas aeruginosagenotypes are common in Australian cystic fibrosis centres
Kidd, T. J., Ramsay, K. A., Hu, H., Marks, G. B., Wainwright, C. E., Bye, P. T. P., Elkins, M. R., Robinson, P. J., Rose, B. R., Wilson, J. W., et al. (2012) · European Respiratory Journal · doi:10.1183/09031936.00060512 · Cited by 67 · see citing works
Is chest CT useful in newborn screened infants with cystic fibrosis at 1 year of age?
Thia, L. P., Calder, A. D., Stocks, J., Bush, A., Owens, C. M., Wallis, C., Young, C., Sullivan, Y., Wade, A. M., McEwan, A. I., et al. (2013) · Thorax · doi:10.1136/thoraxjnl-2013-204176 · Cited by 66 · see citing works
Integrating the multiple breath washout test into international multicentre trials
Saunders, C. J., Jensen, R., Robinson, P. D., Stanojevic, S., Klingel, M. L., Short, C., Davies, J. C., & Ratjen, F. A. (2019) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.11.006 · Cited by 65 · see citing works
Self-citation
The evolution of lung transplantation for cystic fibrosis: A 2017 update
Snell, G. I., Reed, A. K., Stern, M., & Hadjiliadis, D. (2017) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2017.06.008 · Cited by 64 · see citing works
Pulmonary Outcomes Associated with Long-Term Azithromycin Therapy in Cystic Fibrosis
Nichols, D. P., Odem‐Davis, K., Cogen, J. D., Goss, C. H., Ren, C. L., Skalland, M., Somayaji, R., & Heltshe, S. L. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201906-1206oc · Cited by 63 · see citing works
Characterization of Inpatient Cystic Fibrosis Pulmonary Exacerbations
Cogen, J. D., Oron, A. P., Gibson, R. L., Hoffman, L. R., Kronman, M. P., Ong, T., & Rosenfeld, M. (2017) · PEDIATRICS · doi:10.1542/peds.2016-2642 · Cited by 62 · see citing works
Ajulemic acid: potential treatment for chronic inflammation
BURSTEIN, S. H. (2018) · Pharmacology Research & Perspectives · doi:10.1002/prp2.394 · Cited by 61 · see citing works
Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study
Tiddens, H. A. W. M., Boeck, K. D., Clancy, J., Fayon, M. J., Arets, H. G. M., Bresnik, M., Derchak, A., Lewis, S. A., & Oermann, C. M. (2014) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2014.06.003 · Cited by 61 · see citing works
Induced sputum compared to bronchoalveolar lavage in young, non-expectorating cystic fibrosis children
Blau, H., Linnane, B. M., Carzino, R., Tannenbaum, E., Skoric, B., Robinson, P. J., ROBERTSON, C. F., & Ranganathan, S. (2013) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2013.05.013 · Cited by 60 · see citing works
Investigating transmission of Mycobacterium abscessus amongst children in an Australian cystic fibrosis centre
Yan, J., Kevat, A., Martínez, E., Teese, N., Johnson, K., Ranganathan, S., Harrison, J., Massie, J., & Daley, A. J. (2019) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.02.011 · Cited by 60 · see citing works
Cysteamine (Lynovex®), a novel mucoactive antimicrobial & antibiofilm agent for the treatment of cystic fibrosis
Charrier, C., Rodger, C., Robertson, J., Kowalczuk, A., Shand, N., Fraser-Pitt, D. J., Mercer, D. K., & O′Neil, D. A. (2014) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-014-0189-2 · Cited by 59 · see citing works
Inconclusive diagnosis after a positive newborn bloodspot screening result for cystic fibrosis; clarification of the harmonised international definition
Southern, K. W., Barben, J., Gärtner, S., Munck, À., Castellani, C., Mayell, S. J., Davies, J. C., Winters, V., Murphy, J. P., Salinas, D. B., et al. (2019) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.04.010 · Cited by 58 · see citing works
Self-citation
End of life care for patients with cystic fibrosis
Sands, D., Repetto, T., Dupont, L., Korzeniewska, A., Catastini, P., & Madge, S. L. (2011) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(11)60007-6 · Cited by 57 · see citing works
Recent advances in developing therapeutics for cystic fibrosis
Strug, L. J., Stephenson, A. L., Panjwani, N., & Harris, A. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy188 · Cited by 55 · see citing works
Amplifiers co-translationally enhance CFTR biosynthesis via PCBP1-mediated regulation of CFTR mRNA
Dukovski, D., Villella, A., Bastos, C., King, R. W., Finley, D. J., Kelly, J. W., Morimoto, R. I., Hartl, F. U., Muñoz, B., Lee, P., et al. (2020) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2020.02.006 · Cited by 54 · see citing works
Genetic medicines for CF: Hype versus reality
Alton, E. W. F. W., Boyd, A. C., Davies, J. C., Gill, D. R., Griesenbach, U., Harrison, P. T., Henig, N., Higgins, T., Hyde, S. C., Innes, J. A., et al. (2016) · Pediatric Pulmonology · doi:10.1002/ppul.23543 · Cited by 53 · see citing works
Self-citation
Intestinal organoids for Cystic Fibrosis research
de Poel, E., Lefferts, J. W., & Beekman, J. M. (2019) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.11.002 · Cited by 50 · see citing works
Quorum‐sensing inhibition abrogates the deleterious impact of Pseudomonas aeruginosa on airway epithelial repair
Ruffin, M., Bilodeau, C., Maillé, É., LaFayette, S. L., McKay, G. A., Trinh, N. T. N., Beaudoin, T., Desrosiers, M., Rousseau, S., Nguyen, D. M., et al. (2016) · The FASEB Journal · doi:10.1096/fj.201500166r · Cited by 50 · see citing works
Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis
Aslam, A. A., Higgins, C., Sinha, I. P., & Southern, K. W. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012040.pub2 · Cited by 49 · see citing works
Deep resequencing of CFTR in 762 F508del homozygotes reveals clusters of non-coding variants associated with cystic fibrosis disease traits
Vecchio-Pagán, B., Blackman, S. M., Lee, M., Atalar, M., Pellicore, M. J., Pace, R. G., Franca, A., Raraigh, K. S., Sharma, N., Knowles, M. R., et al. (2016) · Human Genome Variation · doi:10.1038/hgv.2016.38 · Cited by 45 · see citing works
Energy balance and obesity in individuals with cystic fibrosis
Litvin, M., Yoon, J. C., Leey, J., Blackman, S. M., & Brennan, A. L. (2019) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.08.015 · Cited by 44 · see citing works
Nutritional Supplementation in Treatment of Cystic Fibrosis of the Pancreas
Allan, J. D. (1973) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/archpedi.1973.02110190018004 · Cited by 44 · see citing works
Phase I Studies of Acebilustat: Biomarker Response and Safety in Patients with Cystic Fibrosis
Elborn, J. S., Horsley, A. R., MacGregor, G., Bilton, D., Grosswald, R., Ahuja, S., & Springman, E. B. (2016) · Clinical and Translational Science · doi:10.1111/cts.12428 · Cited by 44 · see citing works
Bone involvement in young adults with cystic fibrosis awaiting lung transplantation for end-stage respiratory failure
Cairoli, E., Eller-Vainicher, C., Morlacchi, L. C., Tarsia, P., Rossetti, V., Pappalettera, M., Arosio, M., Chiodini, I., & Blasi, F. (2019) · Osteoporosis International · doi:10.1007/s00198-019-04893-z · Cited by 43 · see citing works
Underweight Patients With Cystic Fibrosis Have Acceptable Survival Following Lung Transplantation
Ramos, K. J., Kapnadak, S. G., Bradford, M. C., Somayaji, R., Morrell, E. D., Pilewski, J. M., Lease, E. D., Mulligan, M. S., Aitken, M. L., Gries, C. J., et al. (2020) · Chest · doi:10.1016/j.chest.2019.11.043 · Cited by 42 · see citing works
Modifier genes in cystic fibrosis-related liver disease
Debray, D., Corvol, H., & Housset, C. (2018) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000508 · Cited by 42 · see citing works
Fenretinide differentially modulates the levels of long- and very long-chain ceramides by downregulating Cers5 enzyme: evidence from bench to bedside
Garić, D., Sanctis, J. B. D., Wojewodka, G., Houle, D., Cupri, S., Abu‐Arish, A., Hanrahan, J. W., Hajdúch, M., Matouk, E., & Radzioch, D. (2017) · Journal of Molecular Medicine · doi:10.1007/s00109-017-1564-y · Cited by 41 · see citing works
Nutritional status, nutrient intake and use of enzyme supplements in paediatric patients with Cystic Fibrosis; a European multicentre study with reference to current guidelines
Calvo‐Lerma, J., Hulst, J. M., Asseiceira, I., Claes, I., Garriga, M. J., Colombo, C., Fornés, V., Woodcock, S., Martins, T. F., Boon, M., et al. (2017) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2017.03.005 · Cited by 40 · see citing works
Standardized Measurement of Nasal Membrane Transepithelial Potential Difference (NPD)
Solomon, G. M., Bronsveld, I., Hayes, K., Wilschanski, M. A., Melotti, P., Rowe, S. M., & Sermet‐Gaudelus, I. (2018) · Journal of Visualized Experiments · doi:10.3791/57006 · Cited by 40 · see citing works
Omalizumab for asthma and allergic bronchopulmonary aspergillosis in adults with cystic fibrosis
Koutsokera, A., Corriveau, S., Sykes, J. R., Coriati, A., Cortes, D., Vadas, P., Chaparro, C., McIntyre, K., Tullis, E. D., & Stephenson, A. L. (2019) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.07.011 · Cited by 38 · see citing works
The influence of CFTR complex alleles on precision therapy of cystic fibrosis
Chevalier, B., & Hinzpeter, A. (2019) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.12.008 · Cited by 38 · see citing works
Prevalence and clinical significance of auto-antibodies in adults with cystic fibrosis
Lachenal, F., Nkana, K. N. M., NOVE-JOSSERAND, R., Fabien, N., & Durieu, I. (2009) · European Respiratory Journal · doi:10.1183/09031936.00006009 · Cited by 38 · see citing works
Beyond pancreatic insufficiency and liver disease in cystic fibrosis
Demeyer, S., Boeck, K. D., Witters, P., & Cosaert, K. (2016) · European Journal of Pediatrics · doi:10.1007/s00431-016-2719-5 · Cited by 37 · see citing works
Implementing the international committee on mental health in cystic fibrosis (ICMH) guidelines: screening accuracy and referral-treatment pathways
Verkleij, M., de Winter, D., Hurley, M. A., & Abbott, J. (2018) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2018.02.005 · Cited by 37 · see citing works
Acid Stimulation Reduces Bactericidal Activity of Surface Liquid in Cultured Human Airway Epithelial Cells
Nakayama, K., Jia, Y. X., Hirai, H., Shinkawa, M., Yamaya, M., Sekizawa, K., & Sasaki, H. (2002) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb.26.1.4425 · Cited by 37 · see citing works
Young patients with cystic fibrosis demonstrate subtle alterations of the cardiovascular system
Eising, J. B., van der Ent, C. K., Teske, A. J., Vanderschuren, M. M., Uiterwaal, C. S. P. M., & Meijboom, F. J. (2018) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2017.12.009 · Cited by 37 · see citing works
Probiotics in cystic fibrosis patients: A double blind crossover placebo controlled study
Biervliet, S. V., Hauser, B., Verhulst, S. L., Stepman, H. C. M., Delanghe, J., Warzée, J.-P., Pot, B., de Wiele, T. V., & Wilschanski, M. A. (2018) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2018.06.008 · Cited by 36 · see citing works
Liprotamase Long‐term Safety and Support of Nutritional Status in Pancreatic‐insufficient Cystic Fibrosis
Borowitz, D., Stevens, C. G., Brettman, L. R., Campion, M., Wilschanski, M. A., Thompson, H. C., & Liprotamase 767 Study Group (2011) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0b013e31823315d1 · Cited by 30 · see citing works
Upper versus lower airway microbiome and metagenome in children with cystic fibrosis and their correlation with lung inflammation
Kirst, M. E., Baker, D., Li, E., Abu‐Hasan, M., & Wang, G. P. (2019) · PLoS ONE · doi:10.1371/journal.pone.0222323 · Cited by 29 · see citing works
ISPAD Clinical Practice Consensus Guidelines 2018: What is new in diabetes care?
Ethel Codner, D., Acerini, C. L., Craig, M. E., Hofer, S. E., & Maahs, D. M. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12759 · Cited by 28 · see citing works
Association Between Fat‐Free Mass and Pulmonary Function in Patients With Cystic Fibrosis: A Narrative Review
Gomes, A., Hutcheon, D. A., & Ziegler, J. (2019) · Nutrition in Clinical Practice · doi:10.1002/ncp.10251 · Cited by 27 · see citing works
Predictors of pulmonary exacerbation treatment in cystic fibrosis
Sanders, D. B., Ostrenga, J. S., Rosenfeld, M., Fink, A. K., Schechter, M. S., Sawicki, G. S., Flume, P. A., & Morgan, W. J. (2019) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.06.008 · Cited by 26 · see citing works
Newborn screening programmes for cystic fibrosis
Southern, K. W., & Littlewood, J. M. (2003) · Paediatric Respiratory Reviews · doi:10.1016/s1526-0542(03)00093-9 · Cited by 25 · see citing works
Safety and Efficacy of a Novel Microbial Lipase in Patients with Exocrine Pancreatic Insufficiency due to Cystic Fibrosis: A Randomized Controlled Clinical Trial
Heubi, J. E., Schaeffer, D., Ahrens, R. C., Sollo, N., Strausbaugh, S. D., Graff, G. R., Jain, R., Witte, S., & Forssmann, K. (2016) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2016.05.049 · Cited by 25 · see citing works
Outcomes in cystic fibrosis lung transplant recipients infected with organisms labeled as pan-resistant: An ISHLT Registry‒based analysis
Lay, C., Law, N., Holm, A. M., Benden, C., & Aslam, S. (2019) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2019.01.1306 · Cited by 24 · see citing works
Sildenafil improves vascular endothelial function in patients with cystic fibrosis
Rodriguez‐Miguelez, P., Lee, N., Tucker, M. A., Csányi, G., McKie, K. T., Forseen, C. J., & Harris, R. A. (2018) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00301.2018 · Cited by 24 · see citing works
Palliative Care Needs of Individuals with Cystic Fibrosis: Perspectives of Multiple Stakeholders
Dellon, E. P., Basile, M. J., Hobler, M. R., Georgiopoulos, A. M., Chen, E. Y., Goggin, J. L., Goss, C. H., Hempstead, S. E., Faro, A., & Kavalieratos, D. (2020) · Journal of Palliative Medicine · doi:10.1089/jpm.2019.0464 · Cited by 22 · see citing works
How to use: bacterial cultures in diagnosing lower respiratory tract infections in cystic fibrosis
Ahmed, B., Bush, A., & Davies, J. C. (2013) · Archives of Disease in Childhood Education & Practice · doi:10.1136/archdischild-2012-303408 · Cited by 21 · see citing works
Self-citation
Dissociation of systemic and mucosal autoimmunity in cystic fibrosis
Theprungsirikul, J., Skopelja‐Gardner, S., Meagher, R. E., Clancy, J., Zemanick, E. T., Ashare, A., & Rigby, W. F. C. (2019) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.06.006 · Cited by 20 · see citing works
Ten years of chest MRI for patients with cystic fibrosis
Leutz-Schmidt, P., Eichinger, M., Stahl, M., Sommerburg, O., Biederer, J., Kauczor, H., Puderbach, M., Mall, M. A., & Wielpütz, M. O. (2019) · Der Radiologe · doi:10.1007/s00117-019-0553-2 · Cited by 20 · see citing works
Short-Term Effects of Chest Physiotherapy on Pulmonary Function in Children with Cystic Fibrosis
Weller, P. H., Bush, E., Preece, M. A., & Matthew, D. J. (2009) · Respiration · doi:10.1159/000194251 · Cited by 19 · see citing works
Analysis of a large cohort of cystic fibrosis patients with severe liver disease indicates lung function decline does not significantly differ from that of the general cystic fibrosis population
Polineni, D., Piccorelli, A. V., Hannah, W. B., Dalrymple, S. N., Pace, R. G., Durie, P. R., Ling, S. C., Knowles, M. R., & Stonebraker, J. R. (2018) · PLoS ONE · doi:10.1371/journal.pone.0205257 · Cited by 18 · see citing works
Self-citation
Adults with cystic fibrosis have deficits in bone structure and strength at the distal tibia despite similar size and measuring standard and relative sites
Nishiyama, K. K., Agarwal, S., Kepley, A. L., Rosete, F., Hu, Y., Guo, X., Keating, C. L., DiMango, E., & Shane, E. J. (2017) · Bone · doi:10.1016/j.bone.2017.11.006 · Cited by 17 · see citing works
Effects of a primary palliative care intervention on quality of life and mental health in cystic fibrosis
Friedman, D., Linnemann, R. W., Altstein, L. L., Georgiopoulos, A. M., Islam, S., Bach, K., John, A. S., Fracchia, M. S., Neuringer, I. P., Lapey, A., et al. (2019) · Pediatric Pulmonology · doi:10.1002/ppul.24311 · Cited by 17 · see citing works
Clinical manifestations and risk factors of arthropathy in cystic fibrosis
Roehmel, J. F., Kallinich, T., Staab, D., & Schwarz, C. (2019) · Respiratory Medicine · doi:10.1016/j.rmed.2019.01.003 · Cited by 17 · see citing works
Infection prevention and control in cystic fibrosis: a systematic review of interventions
Rowbotham, N. J., Palser, S. C., Smith, S. J., & Smyth, A. R. (2019) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2019.1595594 · Cited by 17 · see citing works
Elastic aortic properties in cystic fibrosis adults without cardiovascular risk factors: A case‐control study
Vizzardi, E., Sciatti, E., Bonadei, I., Menotti, E., Prati, F., Scodro, M., Dallapellegrina, L., Berlendis, M., Poli, P., Padoan, R., et al. (2019) · Echocardiography · doi:10.1111/echo.14375 · Cited by 16 · see citing works
Clinical outcomes for cystic fibrosis patients with Pseudomonas aeruginosa cross‐infections
Milczewska, J., Wołkowicz, T., Zacharczuk, K., Mierzejewska, E., Kwiatkowska, M., Walicka‐Serzysko, K., & Sands, D. (2019) · Pediatric Pulmonology · doi:10.1002/ppul.24535 · Cited by 16 · see citing works
Prevalence of Bactericidal/Permeability-Increasing Protein Autoantibodies in Cystic Fibrosis Patients: Systematic Review and Meta-Analysis
IWUJI, K. C., Larumbe‐Zabala, E., Bijlani, S., NUGENT, K. M., Kanu, A., Manning, E., & Solis, X. (2019) · Pediatric Allergy Immunology and Pulmonology · doi:10.1089/ped.2018.0970 · Cited by 16 · see citing works
Mental Health Screening of Medically-Admitted Patients With Cystic Fibrosis
García, G., Snell, C., Sawicki, G. S., & Simons, L. E. (2017) · Psychosomatics · doi:10.1016/j.psym.2017.08.010 · Cited by 15 · see citing works
Morphometry versus densitometry ? a comparison by use of casts of human coronary arteries
Doriot, P. A., Suilen, C., Guggenheim, N., Dorsaz, P. ‐., Chappuis, F., & Rutishauser, W. (1992) · International journal of cardiac imaging · doi:10.1007/bf01137533 · Cited by 14 · see citing works
The effect of enteral tube feeding in cystic fibrosis: A registry based study
Libeert, D., Declercq, D., Wanyama, S. S., Thomas, M., daele, S. V., Baets, F. D., & Biervliet, S. V. (2018) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2018.01.004 · Cited by 14 · see citing works
Challenging scenarios in nontuberculous mycobacterial infection in cystic fibrosis
Martiniano, S. L., Esther, C. R., HAWORTH, C. S., Kasperbauer, S. H., Zemanick, E. T., & Caverly, L. J. (2019) · Pediatric Pulmonology · doi:10.1002/ppul.24604 · Cited by 13 · see citing works
Vitamin K supplementation for cystic fibrosis
Jagannath, V. A., Thaker, V., Chang, A. B., & Price, A. I. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008482.pub6 · Cited by 12 · see citing works
Highlights from the 2016 North American Cystic Fibrosis Conference
Zemanick, E. T., Daines, C. L., Dellon, E. P., Esther, C. R., Kinghorn, B., Ong, T., & Muhlebach, M. S. (2017) · Pediatric Pulmonology · doi:10.1002/ppul.23707 · Cited by 11 · see citing works
Burkholderia cepacia complex and limited cutaneous vasculitis in patients with cystic fibrosis: a case series
Kayria, M., Chris, O., Dhasmana, D., Morar, N., Hodson, M. E., Gyi, K. M., Bilton, D., & Simmonds, N. J. (2017) · JRSM Open · doi:10.1177/2054270417692732 · Cited by 10 · see citing works
An innovative phase II trial to establish proof of efficacy and optimal dose of a new inhaled epithelial sodium channel inhibitor BI 1265162 in adults and adolescents with cystic fibrosis: BALANCE-CFTM1
Goss, C. H., Jain, R., Seibold, W., Picard, A.-C., Hsu, M.-C., Gupta, A., & Fajac, I. (2020) · ERJ Open Research · doi:10.1183/23120541.00395-2020 · Cited by 9 · see citing works
Cystic Fibrosis from Childhood to Adulthood
Hota, P. V., & Madan, R. (2020) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2019.12.003 · Cited by 8 · see citing works
Five Cases of Cystic Fibrosis of the Pancreas
Wilmers, M. J., Mackay, H., & ANDERSON, I. M. (1950) · Proceedings of the Royal Society of Medicine · doi:10.1177/003591575004301114 · Cited by 4 · see citing works
Salt Excretion in Sweat in Cystic Fibrosis
Siegenthaler, P., Dubach, U. C., & Haller, R. D. (1963) · JAMA · doi:10.1001/jama.1963.03710130074023 · Cited by 3 · see citing works
Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis
Aslam, A., Sinha, I. P., & Southern, K. W. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012040

Flagged first, then by citations

1 of the 195 references couldn’t be matched to a known paper.

Research works printed but not linked: 2

Saunders, 2016, Developments in multibreath washout testing in children with cystic fibrosis, Curr Med Res Opin, 33, 1
2015, Symposium Summaries, Pediatr Pulmonol, 50, S108

Sorted by citations

CRISPR/Cas9 therapeutics: progress and prospects
Li, T., Yang, Y., Qi, H., Cui, W., Zhang, L., Fu, X., He, X., Liu, M., Li, P., & Yu, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01309-7 · Cited by 770 · see citing works
Worldwide rates of diagnosis and effective treatment for cystic fibrosis
Guo, J., Garratt, A., & Hill, A. M. (2022) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2022.01.009 · Cited by 395 · see citing works
Physiology and pathophysiology of human airway mucus
Hill, D. B., Button, B. M., Rubinstein, M., & Boucher, R. C. (2022) · Physiological Reviews · doi:10.1152/physrev.00004.2021 · Cited by 373 · see citing works
Cystic Fibrosis
Ong, T., & Ramsey, B. W. (2023) · JAMA · doi:10.1001/jama.2023.8120 · Cited by 327 · see citing works
mRNA vaccines in disease prevention and treatment
Zhang, G., Tang, T., Chen, Y., Huang, X., & Liang, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01579-1 · Cited by 253 · see citing works
Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications
Shi, Y., Shi, M., Wáng, Y., & You, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02002-z · Cited by 231 · see citing works
Cystic fibrosis
Mall, M. A., Burgel, P., Castellani, C., Davies, J. C., Salathe, M. A., & Taylor‐Cousar, J. L. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00538-6 · Cited by 223 · see citing works
Self-citation
Molecular structures reveal synergistic rescue of Δ508 CFTR by Trikafta modulators
Fiedorczuk, K., & Chen, J. (2022) · Science · doi:10.1126/science.ade2216 · Cited by 176 · see citing works
CFTR modulator therapy: Transforming the landscape of clinical care in cystic fibrosis
Taylor-Cousar, J. L., Robinson, P. D., Shteinberg, M., & Downey, D. G. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01609-4 · Cited by 173 · see citing works
Self-citation
Cathepsin S (CTSS) activity in health and disease - A treasure trove of untapped clinical potential
Smyth, P., Sasiwachirangkul, J., Williams, R. D., & Scott, C. J. (2022) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2022.101106 · Cited by 150 · see citing works
The future of cystic fibrosis treatment: from disease mechanisms to novel therapeutic approaches
Graeber, S. Y., & Mall, M. A. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01608-2 · Cited by 147 · see citing works
Future therapies for cystic fibrosis
Allen, L., Allen, L. J., Carr, S. B., Davies, G., Downey, D. G., Egan, M. E., Forton, J. T., Gray, R. D., HAWORTH, C. S., Horsley, A. R., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36244-2 · Cited by 143 · see citing works
Self-citation
RNA‐based medicine: from molecular mechanisms to therapy
Sparmann, A., & Vogel, J. (2023) · The EMBO Journal · doi:10.15252/embj.2023114760 · Cited by 141 · see citing works
Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials
Mayer-Hamblett, N., Ratjen, F. A., Russell, R., Donaldson, S. H., Riekert, K. A., Sawicki, G. S., Odem‐Davis, K., Young, J., Rosenbluth, D., Taylor‐Cousar, J. L., et al. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00434-9 · Cited by 140 · see citing works
Mesenchymal stem cells in fibrotic diseases—the two sides of the same coin
Qin, L., Liu, N., Bao, C.-L.-M., Yang, D.-Z., Ma, G.-X., Yi, W.-H., Xiao, G.-Z., & Cao, H.-L. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00952-0 · Cited by 114 · see citing works
CFTR function, pathology and pharmacology at single-molecule resolution
Levring, J., Terry, D. S., Kilic, Z., Fitzgerald, G. A., Blanchard, S. C., & Chen, J. (2023) · Nature · doi:10.1038/s41586-023-05854-7 · Cited by 104 · see citing works
In vitro modulator responsiveness of 655 CFTR variants found in people with cystic fibrosis
Bihler, H. J., Sivachenko, A., Millen, L., Bhatt, P., Thakerar, A., Chin, J., Bailey, V., Musisi, I., LaPan, A., Allaire, N., et al. (2024) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2024.02.006 · Cited by 102 · see citing works
Cystic Fibrosis Modulator Therapies
Jia, S., & Taylor‐Cousar, J. L. (2022) · Annual Review of Medicine · doi:10.1146/annurev-med-042921-021447 · Cited by 97 · see citing works
Opportunistic Pathogens in Cystic Fibrosis: Epidemiology and Pathogenesis of Lung Infection
Blanchard, A. C., & Waters, V. J. (2022) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piac052 · Cited by 93 · see citing works
Impact of elexacaftor/tezacaftor/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF Registry
Sutharsan, S., Dillenhoefer, S., Welsner, M., Stehling, F., Brinkmann, F., Burkhart, M., Ellemunter, H., Dittrich, A., Smaczny, C., Eickmeier, O., et al. (2023) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2023.100690 · Cited by 75 · see citing works
Recruited monocytes/macrophages drive pulmonary neutrophilic inflammation and irreversible lung tissue remodeling in cystic fibrosis
Öz, H. H., Cheng, E.-C., Pietro, C. D., Tebaldi, T., Biancon, G., Zeiss, C. J., Zhang, P., Huang, P. H., Esquibies, S. S., Britto, C. J., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111797 · Cited by 73 · see citing works
Epithelial–Mesenchymal Transition Mechanisms in Chronic Airway Diseases: A Common Process to Target?
Mottais, A., Riberi, L., Falco, A., Soccal, S., Gohy, S. T., & Rose, V. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512412 · Cited by 72 · see citing works
The Changing Epidemiology of Cystic Fibrosis
Burgel, P., Burnet, E., Regard, L., & Martin, C. (2022) · CHEST Journal · doi:10.1016/j.chest.2022.07.004 · Cited by 67 · see citing works
CFTR Modulators in People with Cystic Fibrosis: Real-World Evidence in France
Regard, L., Martin, C., Burnet, E., Silva, J. D., & Burgel, P. (2022) · Cells · doi:10.3390/cells11111769 · Cited by 65 · see citing works
The Tricky Connection between Extracellular Vesicles and Mitochondria in Inflammatory-Related Diseases
Mambro, T. D., Pellielo, G., Agyapong, E. D., Carinci, M., Chianese, D., Giorgi, C., Morciano, G., Patergnani, S., Pinton, P., & Rimessi, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098181 · Cited by 65 · see citing works
The Impact of Highly Effective Modulator Therapy on Cystic Fibrosis Microbiology and Inflammation
Caverly, L. J., Riquelme, S. A., & Hisert, K. B. (2022) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2022.06.007 · Cited by 63 · see citing works
Moonlighting chromatin: when DNA escapes nuclear control
Singh, J., Boettcher, M., Dölling, M., Heuer, A., Hohberger, B., Leppkes, M., Naschberger, E., Schapher, M., Schauer, C., Schoen, J., et al. (2023) · Cell Death and Differentiation · doi:10.1038/s41418-023-01124-1 · Cited by 62 · see citing works
Application of a quantitative framework to improve the accuracy of a bacterial infection model
Lewin, G. R., Kapur, A., Cornforth, D. M., Duncan, R. P., Diggle, F. L., Moustafa, D. A., Harrison, S., Skaar, E. P., Chazin, W., Goldberg, J. B., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2221542120 · Cited by 61 · see citing works
Understanding and addressing the needs of people with cystic fibrosis in the era of CFTR modulator therapy
Hisert, K. B., Birket, S. E., Clancy, J. P., Downey, D. G., Engelhardt, J. F., Fajac, I., Gray, R. D., Lachowicz-Scroggins, M. E., Mayer-Hamblett, N., Thibodeau, P. H., et al. (2023) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(23)00324-7 · Cited by 61 · see citing works
Impact of Elexacaftor/Tezacaftor/Ivacaftor Therapy on the Cystic Fibrosis Airway Microbial Metagenome
Pallenberg, S. T., Pust, M., Rosenboom, I., Hansen, G., Wiehlmann, L., Dittrich, A., & Tümmler, B. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.01454-22 · Cited by 59 · see citing works
Flexible epidermal wearable sensor for Athlete's sweat biomarkers monitoring
Cai, J., Cao, M., Bai, J., Sun, M., Ma, C., Emran, M. Y., Kotb, A., Bo, X., & Zhou, M. (2024) · Talanta · doi:10.1016/j.talanta.2024.126986 · Cited by 59 · see citing works
Pancreatic endocrine and exocrine signaling and crosstalk in physiological and pathological status
Hu, C., Chen, Y., Yin, X., Xu, R., Yin, C., Wang, C., & Zhao, Y. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02098-3 · Cited by 59 · see citing works
The Effect of CFTR Modulators on Airway Infection in Cystic Fibrosis
Harvey, C., Weldon, S., Elborn, J. S., Downey, D. G., & Taggart, C. C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073513 · Cited by 57 · see citing works
Neutralizing antibodies after nebulized phage therapy in cystic fibrosis patients
Bernabéu-Gimeno, M., Pardo-Freire, M., Chan, B. K., Turner, P. E., Gil-Brusola, A., Pérez‐Tarazona, S., Carrasco‐Hernández, L., Quintana‐Gallego, E., & Domingo‐Calap, P. (2024) · Med · doi:10.1016/j.medj.2024.05.017 · Cited by 57 · see citing works
The L467F-F508del Complex Allele Hampers Pharmacological Rescue of Mutant CFTR by Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Patients: The Value of the Ex Vivo Nasal Epithelial Model to Address Non-Responders to CFTR-Modulating Drugs
Sondo, E., Cresta, F., Pastorino, C., Tomati, V., Capurro, V., Pesce, E., Lena, M., Iacomino, M., Baffico, A. M., Coviello, D. A., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063175 · Cited by 56 · see citing works
CFTR Modulator Therapies: Potential Impact on Airway Infections in Cystic Fibrosis
Saluzzo, F., Riberi, L., Messore, B., Lorè, N. I., Esposito, I., Bignamini, E., & Rose, V. D. (2022) · Cells · doi:10.3390/cells11071243 · Cited by 56 · see citing works
The impact of FDA and EMA regulatory decision-making process on the access to CFTR modulators for the treatment of cystic fibrosis
Costa, E., Girotti, S., Pauro, F., Leufkens, H. G. M., & Cipolli, M. (2022) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-022-02350-5 · Cited by 55 · see citing works
Exocrine-Endocrine Crosstalk: The Influence of Pancreatic Cellular Communications on Organ Growth, Function and Disease
Overton, D. L., & Mastracci, T. L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.904004 · Cited by 55 · see citing works
Antibiotic Resistance in Patients with Cystic Fibrosis: Past, Present, and Future
Perikleous, E. P., Gkentzi, D., Bertzouanis, A., Paraskakis, E., Sovtić, A., & Fouzas, S. (2023) · Antibiotics · doi:10.3390/antibiotics12020217 · Cited by 55 · see citing works
Burkholderia cepacia complex in cystic fibrosis: critical gaps in diagnosis and therapy
Gutiérrez‐Santana, J. C., & Coria‐Jiménez, R. (2024) · Annals of Medicine · doi:10.1080/07853890.2024.2307503 · Cited by 55 · see citing works
Organ cross-talk: molecular mechanisms, biological functions, and therapeutic interventions for diseases
Che, H., Gao, Y., Xu, Y., Xu, H., Eils, R., & Tian, M. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02329-1 · Cited by 55 · see citing works
Functional genomics and the future of iPSCs in disease modeling
Brooks, I. R., Garrone, C. M., Kerins, C., Kiar, C. S., Syntaka, S., Xu, J. Z., Spagnoli, F. M., & Watt, F. M. (2022) · Stem Cell Reports · doi:10.1016/j.stemcr.2022.03.019 · Cited by 54 · see citing works
Cystic Fibrosis and Oxidative Stress: The Role of CFTR
Moliteo, E., Sciacca, M., Palmeri, A., Papale, M. R., Manti, S., Parisi, G. F., & Leonardi, S. (2022) · Molecules · doi:10.3390/molecules27165324 · Cited by 54 · see citing works
Gene therapy for cystic fibrosis: Challenges and prospects
Sui, H., Xu, X., Su, Y., Gong, Z., Yao, M., Liu, X., Zhang, T., Jiang, Z., Bai, T., Wang, J., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1015926 · Cited by 51 · see citing works
Pharmacological Improvement of Cystic Fibrosis Transmembrane Conductance Regulator Function Rescues Airway Epithelial Homeostasis and Host Defense in Children with Cystic Fibrosis
Loske, J., Völler, M., Lukassen, S., Stahl, M., Thürmann, L., Seegebarth, A., Roehmel, J. F., Wisniewski, S., Messingschlager, M., Lorenz, S., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202310-1836oc · Cited by 51 · see citing works
Microbial Epidemiology of the Cystic Fibrosis Airways: Past, Present, and Future
Thornton, C. S., & Parkins, M. D. (2023) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0042-1758732 · Cited by 49 · see citing works
Genetics and epigenetics of chronic rhinosinusitis
Lal, D., Brar, T. K., Ramkumar, S. P., Li, J., Kato, A., & Zhang, L. (2023) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2023.01.004 · Cited by 49 · see citing works
Novel inhalation therapy in pulmonary fibrosis: principles, applications and prospects
Zheng, M., Zhu, W., Gao, F., Zhuo, Y., Mo, Z., Wu, G., & Feng, C. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02407-6 · Cited by 50 · see citing works
Multisystemic Effects of Elexacaftor–Tezacaftor–Ivacaftor in Adults with Cystic Fibrosis and Advanced Lung Disease
Burgel, P., Paillasseur, J.-L., Durieu, I., Reynaud‐Gaubert, M., Hamidfar, R., Murris‐Espin, M., Danner‐Boucher, I., Chiron, R., Leroy, S., Douvry, B., et al. (2024) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202312-1065oc · Cited by 47 · see citing works
Lentiviral Gene Therapy for Cystic Fibrosis: A Promising Approach and First-in-Human Trial
Davies, J. C., Polineni, D., Boyd, A. C., Donaldson, S. H., Gill, D. R., Uta Griesenbach, D., Hyde, S. C., Jain, R., McLachlan, G., Mall, M. A., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202402-0389ci · Cited by 47 · see citing works
Self-citation
Assays of CFTR Function In Vitro, Ex Vivo and In Vivo
Ramalho, A. S., Boon, M., Proesmans, M., Vermeulen, F. L., Carlon, M. S., & Boeck, K. D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031437 · Cited by 47 · see citing works
Molecular Prerequisites for Neutrophil Extracellular Trap Formation and Evasion Mechanisms of Staphylococcus aureus
von Köckritz‐Blickwede, M., & Winstel, V. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.836278 · Cited by 46 · see citing works
CFTR Modulators: Current Status and Evolving Knowledge
Regard, L., Martin, C., Silva, J. D., & Burgel, P. (2022) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0042-1758851 · Cited by 44 · see citing works
SARS-CoV-2 envelope protein impairs airway epithelial barrier function and exacerbates airway inflammation via increased intracellular Cl− concentration
Xu, J.-B., Guan, W., Zhang, Y., Qiu, Z.-E., Chen, L., Hou, X.-C., Yue, J., Zhou, Y.-Y., Sheng, J., Zhao, L., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01753-z · Cited by 43 · see citing works
Prophylactic and therapeutic vaccine development: advancements and challenges
Weerarathna, I. N., Doelakeh, E. S., Kiwanuka, L., Kumar, P., & Arora, S. (2024) · Molecular Biomedicine · doi:10.1186/s43556-024-00222-x · Cited by 43 · see citing works
The Distribution and Role of the CFTR Protein in the Intracellular Compartments
Łukasiak, A., & Zając, M. (2021) · Membranes · doi:10.3390/membranes11110804 · Cited by 42 · see citing works
Cystic fibrosis transmembrane conductance regulator modulators and the exocrine pancreas: A scoping review
Ramsey, M. L., Li, S. S., Lara, L. F., Gokun, Y., Akshintala, V. S., Conwell, D. L., Heintz, J., Kirkby, S. E., McCoy, K., Papachristou, G. I., et al. (2022) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2022.08.008 · Cited by 42 · see citing works
Ion Channels and Transporters as Therapeutic Agents: From Biomolecules to Supramolecular Medicinal Chemistry
Picci, G., Marchesan, S., & Caltagirone, C. (2022) · Biomedicines · doi:10.3390/biomedicines10040885 · Cited by 41 · see citing works
A succinate/SUCNR1-brush cell defense program in the tracheal epithelium
Perniss, A., Boonen, B., Tonack, S., Thiel, M., Poharkar, K. V., Alnouri, M. W., Keshavarz, M., Papadakis, T., Wiegand, S., Pfeil, U., et al. (2023) · Science Advances · doi:10.1126/sciadv.adg8842 · Cited by 39 · see citing works
Revisiting Host-Pathogen Interactions in Cystic Fibrosis Lungs in the Era of CFTR Modulators
Ribeiro, C. M. P., Higgs, M. G., Muhlebach, M. S., Wolfgang, M. C., Borgatti, M., Lampronti, I., & Cabrini, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24055010 · Cited by 39 · see citing works
Genome Editing for Cystic Fibrosis
Wang, G. (2023) · Cells · doi:10.3390/cells12121555 · Cited by 38 · see citing works
Cystic Fibrosis and Cancer: Unraveling the Complex Role of CFTR Gene in Cancer Susceptibility
Parisi, G. F., Papale, M. R., Pecora, G., Rotolo, N., Manti, S., Russo, G. M., & Leonardi, S. (2023) · Cancers · doi:10.3390/cancers15174244 · Cited by 38 · see citing works
Bicarbonate Transport in Cystic Fibrosis and Pancreatitis
Angyal, D., Bijvelds, M. J. C., Bruno, M. J., Peppelenbosch, M. P., & de Jonge, H. R. (2021) · Cells · doi:10.3390/cells11010054 · Cited by 37 · see citing works
Antisense Oligonucleotide Therapeutics for Cystic Fibrosis: Recent Developments and Perspectives
Kim, Y. J., & Krainer, A. R. (2023) · Molecules and Cells · doi:10.14348/molcells.2023.2172 · Cited by 36 · see citing works
Nutritional Status and Circulating Levels of Fat-Soluble Vitamins in Cystic Fibrosis Patients: A Cohort Study and Evaluation of the Effect of CFTR Modulators
Francalanci, M., Terlizzi, V., Fevola, C., Rosa, G. D., Pierattini, V., Roselli, E., Bonomi, P., Cavicchi, M. C., Galici, V., Neri, A. S., et al. (2023) · Children · doi:10.3390/children10020252 · Cited by 36 · see citing works
Functional restoration of a CFTR splicing mutation through RNA delivery of CRISPR adenine base editor
Amistadi, S., Maule, G., Ciciani, M., Ensinck, M. M., Keersmaecker, L. D., Ramalho, A. S., Guidone, D., Buccirossi, M., Galietta, L. J. V., Carlon, M. S., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.03.004 · Cited by 35 · see citing works
Advancing the pipeline of cystic fibrosis clinical trials: a new roadmap with a global trial network perspective
Mayer-Hamblett, N., Clancy, J. P., Jain, R., Donaldson, S. H., Fajac, I., Goss, C. H., Polineni, D., Ratjen, F. A., Quon, B. S., Zemanick, E. T., et al. (2023) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(23)00297-7 · Cited by 34 · see citing works
Self-citation
Adherence, reliability, and variability of home spirometry telemonitoring in cystic fibrosis
Beaufils, F., Enaud, R., Galodé, F., Boucher, G., Macey, J., Berger, P., Fayon, M. J., & Bui, S. (2023) · Frontiers in Pediatrics · doi:10.3389/fped.2023.1111088 · Cited by 33 · see citing works
Cystic fibrosis-related mortality in the United States from 1999 to 2020: an observational analysis of time trends and disparities
Singh, H., Jani, C., Marshall, D. C., Franco, R., Bhatt, P. S., Podder, S., Shalhoub, J., Kurman, J. S., Nanchal, R. S., Uluer, A., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-41868-x · Cited by 33 · see citing works
Challenges of Antimicrobial Resistance and Stewardship in Solid Organ Transplant Patients
So, M., & Walti, L. N. (2022) · Current Infectious Disease Reports · doi:10.1007/s11908-022-00778-1 · Cited by 32 · see citing works
Microevolution of Pseudomonas aeruginosa in the airways of people with cystic fibrosis
Cramer, N., Klockgether, J., & Tümmler, B. (2023) · Current Opinion in Immunology · doi:10.1016/j.coi.2023.102328 · Cited by 32 · see citing works
Future Comorbidities in an Aging Cystic Fibrosis Population
Ticona, J. H., Lapinel, N. C., & Wang, J. (2023) · Life · doi:10.3390/life13061305 · Cited by 32 · see citing works
Intestinal dysbiosis and inflammation in cystic fibrosis impacts gut and multi-organ axes
Wrigley-Carr, H., van Dorst, J. M., & Ooi, C. Y. (2022) · Medicine in Microecology · doi:10.1016/j.medmic.2022.100057 · Cited by 31 · see citing works
Simultaneous Quantification of Ivacaftor, Tezacaftor, and Elexacaftor in Cystic Fibrosis Patients’ Plasma by a Novel LC–MS/MS Method
Pigliasco, F., Cafaro, A., Stella, M., Baiardi, G., Barco, S., Pedemonte, N., D’Orsi, C., Cresta, F., Casciaro, R., Castellani, C., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11020628 · Cited by 31 · see citing works
Open reading frame correction using splice-switching antisense oligonucleotides for the treatment of cystic fibrosis
Michaels, W. E., Peña‐Rasgado, C., Kotaria, R., Bridges, R. J., & Hastings, M. L. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2114886119 · Cited by 31 · see citing works
Improved Nutritional Outcomes and Gastrointestinal Symptoms in Adult Cystic Fibrosis Patients Treated with Elexacaftor/Tezacaftor/Ivacaftor
Šťastná, N., Kunovský, L., Svoboda, M., Pokojová, E., Homola, L., Malá, M., Gracova, Z., Jeřábková, B., Skřičková, J., & Trna, J. (2024) · Digestive Diseases · doi:10.1159/000538606 · Cited by 30 · see citing works
Nano Approaches to Nucleic Acid Delivery: Barriers, Solutions, and Current Landscape
Gonzalez, J. C., Park, K. W., Evans, D. B., Sharma, R. B., Sahaym, O., Gopalakrishnan, S., Dar, A. I., Valdez, T. A., & Sharma, A. (2025) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.70010 · Cited by 30 · see citing works
Allergic bronchopulmonary aspergillosis: A multidisciplinary review
Roboubi, A., Audousset, C., Fréalle, É., Brun, A., Laurent, F., Vitte, J., Mortuaire, G., Lefèvre, G., Cadranel, J. L., & Chenivesse, C. (2023) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2023.101392 · Cited by 30 · see citing works
A decade of liver organoids: Advances in disease modeling
Liu, Y., Sheng, J.-Y., Yang, C.-F., Ding, J., & Chan, Y.-S. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0428 · Cited by 30 · see citing works
Pathophysiological role of ion channels and transporters in gastrointestinal mucosal diseases
Deng, Z., Zhao, Y., Ma, Z., Zhang, M., Wang, H., Yi, Z., Tuo, B., Li, T., & Liu, X. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-04011-5 · Cited by 29 · see citing works
Disarm The Bacteria: What Temperate Phages Can Do
Zhou, S., Liu, Z., Song, J., & Chen, Y. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45020076 · Cited by 29 · see citing works
Breaching Bacterial Biofilm Barriers: Efficient Combinatorial Theranostics for Multidrug-Resistant Bacterial Biofilms with a Novel Penetration-Enhanced AIEgen Probe
Liu, X., Fan, D., Feng, X., Zheng, Y., Wegner, S. V., Liu, M., Chen, F., & Zeng, W. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c07378 · Cited by 28 · see citing works
Mixed Populations and Co-Infection: Pseudomonas aeruginosa and Staphylococcus aureus
Camus, L., Briaud, P., Vandenesch, F., Doléans-Jordheim, A., & Moreau, K. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-08491-1_15 · Cited by 28 · see citing works
Neutrophil serine proteases in cystic fibrosis: role in disease pathogenesis and rationale as a therapeutic target
Mall, M. A., Davies, J. C., Donaldson, S. H., Jain, R., Chalmers, J. D., & Shteinberg, M. (2024) · European Respiratory Review · doi:10.1183/16000617.0001-2024 · Cited by 27 · see citing works
Self-citation
Mutual Effects of Single and Combined CFTR Modulators and Bacterial Infection in Cystic Fibrosis
Cigana, C., Giannella, R., Colavolpe, A., Alcalá-Franco, B., Mancini, G., Colombi, F., Bigogno, C., Bastrup, U., Bertoni, G., & Bragonzi, A. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.04083-22 · Cited by 27 · see citing works
Folding correctors can restore CFTR posttranslational folding landscape by allosteric domain–domain coupling
Soya, N., Xu, H., Roldán, A., Yang, Z. W., Ye, H. L., Jiang, F., Premchandar, A., Veit, G., Cole, S. P. C., Kappes, J. C., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42586-8 · Cited by 27 · see citing works
Diversity of CFTR variants across ancestries characterized using 454,727 UK biobank whole exome sequences
Ideozu, J. E., Liu, M., Riley-Gillis, B. M., Paladugu, S. R., Rahimov, F., Krishnan, P., Tripathi, R. L., Dorr, P. K., Levy, H., Singh, A. K., et al. (2024) · Genome Medicine · doi:10.1186/s13073-024-01316-5 · Cited by 27 · see citing works
Channels and Transporters of the Pulmonary Lamellar Body in Health and Disease
Dietl, P., & Frick, M. (2021) · Cells · doi:10.3390/cells11010045 · Cited by 26 · see citing works
A PI3Kγ mimetic peptide triggers CFTR gating, bronchodilation, and reduced inflammation in obstructive airway diseases
Ghigo, A., Murabito, A., Sala, V., Pisano, A. R., Bertolini, S., Gianotti, A., Caci, E., Montresor, A., Premchandar, A., Pirozzi, F., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abl6328 · Cited by 26 · see citing works
CFTR mutations and phenotypic correlations in people with cystic fibrosis: a retrospective study from a single centre in south India
Varkki, S. D., Aaron, R., Chapla, A., Danda, S., Medhi, P., Rani, N. J., & Paul, G. (2024) · The Lancet Regional Health - Southeast Asia · doi:10.1016/j.lansea.2024.100434 · Cited by 26 · see citing works
Diversity and prevalence of type VI secretion system effectors in clinical Pseudomonas aeruginosa isolates
Robinson, L. A., Collins, A. C. Z., Murphy, R. A., Davies, J. C., & Allsopp, L. P. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1042505 · Cited by 26 · see citing works
Self-citation
Neutrophil-derived biomarkers in bronchiectasis: identifying a common therapeutic target
Chalmers, J. D., Mall, M. A., Nielsen, K. G., Chang, A. B., Aliberti, S., Blasi, F., Korkmaz, B., Lorent, N., Taggart, C. C., & Loebinger, M. R. (2025) · European Respiratory Journal · doi:10.1183/13993003.00081-2025 · Cited by 25 · see citing works
Clinical outcomes of a large cohort of individuals with the F508del/5T;TG12 CFTR genotype
Tosco, A., Castaldo, A., Colombo, C., Claut, L. E., Carnovale, V., Iacotucci, P., Lucarelli, M., Cimino, G. G., Fabrizzi, B., Caporelli, N., et al. (2022) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2022.04.020 · Cited by 25 · see citing works
Hydrogen Sulfide: A Gaseous Mediator and Its Key Role in Programmed Cell Death, Oxidative Stress, Inflammation and Pulmonary Disease
Zhu, Z., Lian, X., & Bhatia, M. (2022) · Antioxidants · doi:10.3390/antiox11112162 · Cited by 25 · see citing works
Inflammation and Infection in Cystic Fibrosis: Update for the Clinician
Petrocheilou, A., Moudaki, A., & Kaditis, A. G. (2022) · Children · doi:10.3390/children9121898 · Cited by 25 · see citing works
Influence of highly effective modulator therapy on the sputum proteome in cystic fibrosis
Maher, R. E., Barry, P. J., Emmott, E., Jones, A. M., Lijing Lin, A., McNamara, P. S., Smith, J. A., & Lord, R. W. (2023) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2023.10.019 · Cited by 25 · see citing works
Targeting the E1 ubiquitin-activating enzyme (UBA1) improves elexacaftor/tezacaftor/ivacaftor efficacy towards F508del and rare misfolded CFTR mutants
Borgo, C., D’Amore, C., Capurro, V., Tomati, V., Sondo, E., Cresta, F., Castellani, C., Pedemonte, N., & Salvi, M. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04215-3 · Cited by 24 · see citing works
Digestive outcomes in Cystic fibrosis
Ley, D., & Turck, D. (2022) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2022.101788 · Cited by 24 · see citing works
Permeability-driven pressure and cell proliferation control lumen morphogenesis in pancreatic organoids
Lee, B. H., Fuji, K., Petzold, H., Seymour, P. A., Yennek, S., Schewin, C., Lewis, A., Riveline, D., Hiraiwa, T., Sano, M., et al. (2025) · Nature Cell Biology · doi:10.1038/s41556-025-01832-5 · Cited by 23 · see citing works
Overview of CF lung pathophysiology
Cabrini, G., Rimessi, A., Borgatti, M., Pinton, P., & Gambari, R. (2022) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2022.102214 · Cited by 23 · see citing works

Authors: Shteinberg, M., Haq, I. J., Polineni, D., & Davies, J. C.
Affiliations: Technion – Israel Institute of Technology (IL)
Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
University of Kansas Medical Center (US)
Guy's and St Thomas' NHS Foundation Trust (GB)
ORCID: Shteinberg, Michal
Haq, Iram J
Polineni, Deepika
Davies, Jane C
Venue: The Lancet
Publisher: Elsevier BV
Published: 2021-06
Volume: 397
Issue: 10290
Pages: 2195-2211
ISSN: 0099-5355 (ISSN-L)
0140-6736
DOI: 10.1016/s0140-6736(20)32542-3
OpenAlex: W4205612199
Cited by: 682
References: 195
Citations by year: 2026: 96 · 2025: 132 · 2024: 147 · 2023: 160 · 2022: 131 · 2021: 14 · 2013: 1
FWCI: 18.21
Type: journal article
Language: en
Open access: green
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: The Lancet (publishedVersion)
PubMed (publishedVersion)
Newcastle University ePrints (Newcastle Univesity)
Funders: National Institute for Health and Care Research (NIHR201402, CL-2018-01-002)
Cystic Fibrosis Trust (SRC 014)
Academy of Medical Sciences (SGL024\1027)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cystic Fibrosis Research Advances
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Kidney Cyst Diseases
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Neonatal Respiratory Health Research
Keywords: cystic fibrosis, CFTR mutations, CFTR function, mucus hydration, chronic lung infection, exocrine pancreatic insufficiency, male infertility, cystic fibrosis-related diabetes, cystic fibrosis liver disease, newborn screening, sweat test, CFTR modulator therapy, mucociliary clearance, disease pathophysiology, multidisciplinary care
MeSH terms: Bicarbonates, Chlorides, Cystic Fibrosis, Humans, Life Expectancy, Mucociliary Clearance, Mutation, Exocrine Pancreatic Insufficiency, Genetic Therapy, Cystic Fibrosis Transmembrane Conductance Regulator, Disease Management

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cystic fibrosis

Abstract

Integrity signals

Claims the paper makes

Cites

Cited by

Related

Record

About these checks